1xbet 한국., Ltd.

1xbet 한국., Ltd. (Otsuka) announces that it has filed an application in Japan for an additional indication for Rexulti^® (generic name: brexpiprazole) in the treatment of agitation associated with dementia　due to Alzheimer's disease. If approved, brexpiprazole would be the first pharmacological treatment indicated 1xbet 한국 agitation in patients with dementia　due to Alzheimer's disease in Japan.

1xbet 한국 phase 3 clinical trial in Japan evaluated 1xbet 한국 efficacy and safety of brexpiprazole (1mg/day and 2mg/day) versus placebo over ten weeks in 1xbet 한국 treatment of 410 adult patients aged 55 to 90 with agitation associated with dementia　due to Alzheimer's disease. 1xbet 한국 study's primary endpoint was attained, demonstrating a statistically significant improvement in 1xbet 한국 Cohen-Mansfield Agitation Inventory (CMAI) total score of 1xbet 한국 groups administered brexpiprazole 1mg/day or 2mg/day compared with 1xbet 한국 placebo group. Improvement was also observed in secondary endpoints such as 1xbet 한국 Clinical Global Impression-Severity Illness (CGI-S) score in 1xbet 한국 1mg/day and 2mg/day brexpiprazole groups compared with 1xbet 한국 placebo group. Brexpiprazole was generally well tolerated, and no new safety signals were observed.

1xbet 한국 will continue to deliver innovative products to meet unmet medical needs around the world.